Rubin Lab

Publications

Found 91 results
Filters: First Letter Of Last Name is G  [Clear All Filters]
2011
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..  2011.  The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..  2011.  The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..  2011.  The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..  2011.  The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.
Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..  2011.  The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.
Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discov. 1(6):487-95.
Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discov. 1(6):487-95.
Svensson MA, Lafargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa-Cruz AM, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS et al..  2011.  Testing mutual exclusivity of ETS rearranged prostate cancer.. Lab Invest. 91(3):404-12.
2010
Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, Jarleborn AR, Hofer MD, Kuefer R, Demichelis F et al..  2010.  ERG rearrangement metastasis patterns in locally advanced prostate cancer.. Urology. 75(4):762-7.
Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, Tewari AK, Kitabayashi N, Moss BJ, Chee MS et al..  2010.  FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data.. Genome Biol. 11(10):R104.
Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami H-O, Fall K, Mucci LA et al..  2010.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.. BMC Med Genomics. 3:8.
Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami H-O, Fall K, Mucci LA et al..  2010.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.. BMC Med Genomics. 3:8.
2009
Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A et al..  2009.  Distinct genomic aberrations associated with ERG rearranged prostate cancer.. Genes Chromosomes Cancer. 48(4):366-80.
Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M et al..  2009.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 27(21):3459-64.
Pflueger D, Rickman DS, Sboner A, Perner S, Lafargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A et al..  2009.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.. Neoplasia. 11(8):804-11.
Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.
Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.
Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H et al..  2009.  TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.. J Pathol. 217(1):65-72.
2008
Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K, Storz M, Scherrer S, Schmid DM, Strebel RT et al..  2008.  Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer.. Int J Cancer. 123(3):569-76.
Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G et al..  2008.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.. Clin Cancer Res. 14(11):3380-5.
Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ et al..  2008.  EML4-ALK fusion lung cancer: a rare acquired event.. Neoplasia. 10(3):298-302.
Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA et al..  2008.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. J Natl Cancer Inst. 100(11):815-25.
Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA.  2008.  SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.. Nucleic Acids Res. 36(7):2446-56.
Demichelis F, Greulich H, Macoska JA, Beroukhim R, Sellers WR, Garraway L, Rubin MA.  2008.  SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines.. Nucleic Acids Res. 36(7):2446-56.
2007
Setlur SR, Royce TE, Sboner A, Mosquera J-M, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA.  2007.  Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer.. Cancer Res. 67(21):10296-303.